{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Acute+Moderate-to-severe+Pain&page=4",
    "query": {
      "condition": "Acute Moderate-to-severe Pain",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 88,
    "total_pages": 9,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Acute+Moderate-to-severe+Pain&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Acute+Moderate-to-severe+Pain&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-06T03:04:56.568Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05737121",
      "title": "Safety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidocaine and Heparin) or Placebo in Subjects With IC/BPS",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Interstitial Cystitis",
        "Bladder Pain Syndrome"
      ],
      "interventions": [
        {
          "name": "VNX001",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Lidocaine",
          "type": "DRUG"
        },
        {
          "name": "Heparin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vaneltix Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2023-05-22",
      "completion_date": "2026-06",
      "has_results": false,
      "last_update_posted_date": "2026-01-22",
      "last_synced_at": "2026-10-06T03:04:56.568Z",
      "location_count": 14,
      "location_summary": "Escondido, California • Los Angeles, California • Newport Beach, California + 10 more",
      "locations": [
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05737121"
    },
    {
      "nct_id": "NCT02447848",
      "title": "Open-Label Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg for Acute Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Moderate-to-severe Acute Pain"
      ],
      "interventions": [
        {
          "name": "sufentanil sublingual 30 mcg tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Talphera, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 76,
      "start_date": "2015-10",
      "completion_date": "2016-07",
      "has_results": true,
      "last_update_posted_date": "2017-10-19",
      "last_synced_at": "2026-10-06T03:04:56.568Z",
      "location_count": 3,
      "location_summary": "Minneapolis, Minnesota • Houston, Texas",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02447848"
    },
    {
      "nct_id": "NCT01016808",
      "title": "Comparison of the Efficacy and Safety of Q8003 Versus Its Individual Components in Bunionectomy Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Moderate to Severe Postoperative Pain"
      ],
      "interventions": [
        {
          "name": "Q8003",
          "type": "DRUG"
        },
        {
          "name": "Morphine sulfate",
          "type": "DRUG"
        },
        {
          "name": "Oxycodone HCl",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "QRxPharma Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 522,
      "start_date": "2009-12",
      "completion_date": "2010-03",
      "has_results": false,
      "last_update_posted_date": "2012-05-17",
      "last_synced_at": "2026-10-06T03:04:56.568Z",
      "location_count": 5,
      "location_summary": "Anaheim, California • Owings Mills, Maryland • Pasadena, Maryland + 2 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Owings Mills",
          "state": "Maryland"
        },
        {
          "city": "Pasadena",
          "state": "Maryland"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01016808"
    },
    {
      "nct_id": "NCT00348491",
      "title": "Efficacy of Lumiracoxib in Relieving Moderate to Severe Post-dental Surgery Pain, Compared to Both Placebo and Celecoxib",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pain"
      ],
      "interventions": [
        {
          "name": "Lumiracoxib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "17 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "17 Years and older"
      },
      "enrollment_count": 364,
      "start_date": "2006-02",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2017-02-23",
      "last_synced_at": "2026-10-06T03:04:56.568Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00348491"
    },
    {
      "nct_id": "NCT02662556",
      "title": "A Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg in Patients With Post-Operative Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Moderate-to-severe Pain"
      ],
      "interventions": [
        {
          "name": "sufentanil sublingual tablet 30 mcg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Talphera, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 140,
      "start_date": "2016-03",
      "completion_date": "2016-07",
      "has_results": true,
      "last_update_posted_date": "2017-03-15",
      "last_synced_at": "2026-10-06T03:04:56.568Z",
      "location_count": 2,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02662556"
    },
    {
      "nct_id": "NCT03782792",
      "title": "Effisayil™ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Generalized Pustular Psoriasis"
      ],
      "interventions": [
        {
          "name": "Spesolimab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 53,
      "start_date": "2019-01-31",
      "completion_date": "2021-01-05",
      "has_results": true,
      "last_update_posted_date": "2025-10-16",
      "last_synced_at": "2026-10-06T03:04:56.568Z",
      "location_count": 4,
      "location_summary": "Birmingham, Alabama • Miami, Florida • Tampa, Florida + 1 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03782792"
    },
    {
      "nct_id": "NCT00119158",
      "title": "Combination Therapy for Atopic Dermatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "Combination of pimecrolimus and fluticasone",
          "type": "DRUG"
        },
        {
          "name": "pimecrolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's Hospital of Philadelphia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "2 Years to 65 Years"
      },
      "enrollment_count": 90,
      "start_date": "2004-10",
      "completion_date": "2005-06",
      "has_results": true,
      "last_update_posted_date": "2010-07-27",
      "last_synced_at": "2026-10-06T03:04:56.568Z",
      "location_count": 3,
      "location_summary": "Denver, Colorado • Chicago, Illinois • Houston, Texas",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00119158"
    },
    {
      "nct_id": "NCT02746263",
      "title": "Multicenter Study to Compare Intravenous and Oral Acetaminophen for the Treatment of Acute Moderate to Severe Pain",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Acute Pain, Postoperative"
      ],
      "interventions": [
        {
          "name": "IV acetaminophen",
          "type": "DRUG"
        },
        {
          "name": "Oral acetaminophen",
          "type": "DRUG"
        },
        {
          "name": "Morphine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mallinckrodt",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "50 Years to 90 Years"
      },
      "enrollment_count": 1,
      "start_date": "2016-04-27",
      "completion_date": "2016-05-05",
      "has_results": true,
      "last_update_posted_date": "2019-11-19",
      "last_synced_at": "2026-10-06T03:04:56.568Z",
      "location_count": 2,
      "location_summary": "Pensacola, Florida • Columbus, Ohio",
      "locations": [
        {
          "city": "Pensacola",
          "state": "Florida"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02746263"
    },
    {
      "nct_id": "NCT04645953",
      "title": "Staccato Granisetron® (AZ 010) for the Treatment of Cyclic Vomiting Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cyclic Vomiting Syndrome"
      ],
      "interventions": [
        {
          "name": "3mg AZ-010",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "1mg AZ010",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Staccato Placebo",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Alexza Pharmaceuticals, Inc.",
      "sponsor_class": "UNKNOWN",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 150,
      "start_date": "2021-02-05",
      "completion_date": "2022-07-26",
      "has_results": true,
      "last_update_posted_date": "2025-06-11",
      "last_synced_at": "2026-10-06T03:04:56.568Z",
      "location_count": 18,
      "location_summary": "Lancaster, California • Los Angeles, California • San Diego, California + 14 more",
      "locations": [
        {
          "city": "Lancaster",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Athens",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04645953"
    },
    {
      "nct_id": "NCT05386472",
      "title": "A Study to Learn About the Study Medicine (Nirmatrelvir Plus Ritonavir) in Pregnant Women With COVID-19",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "nirmatrelvir",
          "type": "DRUG"
        },
        {
          "name": "ritonavir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 25,
      "start_date": "2022-06-22",
      "completion_date": "2025-05-13",
      "has_results": false,
      "last_update_posted_date": "2026-08-17",
      "last_synced_at": "2026-10-06T03:04:56.568Z",
      "location_count": 13,
      "location_summary": "Birmingham, Alabama • Cutler Bay, Florida • DeBary, Florida + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Cutler Bay",
          "state": "Florida"
        },
        {
          "city": "DeBary",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05386472"
    }
  ]
}